|Memantine for prophylactic treatment of migraine without aura: A randomized double‐blind placebo‐controlled study|
R Noruzzadeh, A Modabbernia, V Aghamollaii, M Ghaffarpour, ...
Headache: The Journal of Head and Face Pain 56 (1), 95-103, 2016
|Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial|
M Ahmadi, E Agah, S Nafissi, MR Jaafari, MH Harirchian, P Sarraf, ...
Neurotherapeutics 15 (2), 430-438, 2018
|Serum and CSF PDGF‐AA and FGF‐2 in relapsing‐remitting multiple sclerosis: a case–control study|
MH Harirchian, AH Tekieh, A Modabbernia, V Aghamollaii, A Tafakhori, ...
European journal of neurology 19 (2), 241-247, 2012
|Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis|
F Rahmani, A Saghazadeh, M Rahmani, AL Teixeira, N Rezaei, ...
Brain research 1704, 127-136, 2019
|Sensing of Alzheimer’s disease and multiple sclerosis using nano-bio interfaces|
MJ Hajipour, F Ghasemi, H Aghaverdi, M Raoufi, U Linne, F Atyabi, ...
Journal of Alzheimer's Disease 59 (4), 1187-1202, 2017
|PTRHD1 (C2orf79) mutations lead to autosomal‐recessive intellectual disability and parkinsonism|
H Khodadadi, LJ Azcona, V Aghamollaii, MD Omrani, M Garshasbi, ...
Movement Disorders 32 (2), 287-291, 2017
|Sympathetic skin response (SSR) in multiple sclerosis and clinically isolated syndrome: a case-control study|
V Aghamollaii, MH Harirchian, A Modabbernia, M Ghaffarpour, M Mousavi, ...
Neurophysiologie Clinique/Clinical Neurophysiology 41 (4), 161-171, 2011
|Should we think of Urbach–Wiethe disease in refractory epilepsy? Case report and review of the literature|
HG Omrani, M Tajdini, B Ghelichnia, SMR Hosseini, A Tafakhori, ...
Journal of the neurological sciences 320 (1-2), 149-152, 2012
|Adie's pupil during migraine attack: case report and review of literature.|
A Tafakhori, V Aghamollaii, A Modabbernia, H Pourmahmoodian
Acta neurologica belgica 111 (1), 66, 2011
|Evaluating executive function in patients with temporal lobe epilepsy using the frontal assessment battery|
E Agah, N Asgari-Rad, M Ahmadi, A Tafakhori, V Aghamollaii
Epilepsy Research 133, 22-27, 2017
|Attentional bias towards and away from fearful faces is modulated by developmental amygdala damage|
M Pishnamazi, A Tafakhori, S Loloee, A Modabbernia, V Aghamollaii, ...
cortex 81, 24-34, 2016
|Biphasic effect of sumatriptan on PTZ-induced seizures in mice: Modulation by 5-HT1B/D receptors and NOS/NO pathway|
M Gooshe, K Ghasemi, MM Rohani, A Tafakhori, S Amiri, V Aghamollaii, ...
European journal of pharmacology 824, 140-147, 2018
|Epileptic syndromes: From clinic to genetic|
A Tafakhori, V Aghamollaii, S Faghihi-Kashani, P Sarraf, L Habibi
Iranian journal of neurology 14 (1), 1, 2015
|From a simple chronic headache to neurobrucellosis: a case report|
M Tajdini, S Akbarloo, SMR Hosseini, B Parvizi, S Baghani, V Aghamollaii, ...
Medical journal of the Islamic Republic of Iran 28, 12, 2014
|Potential diagnostic value of 131I-MIBG myocardial scintigraphy in discrimination between Alzheimer disease and dementia with Lewy bodies|
M Abbasi, N Ghalandari, S Farzanefar, V Aghamollaii, M Ahmadi, M Ganji, ...
Clinical neurology and neurosurgery 163, 163-166, 2017
|Plasma neurofilament light chain levels are associated with cortical hypometabolism in Alzheimer disease signature regions|
M Mayeli, SM Mirshahvalad, V Aghamollaii, A Tafakhori, A Abdolalizadeh, ...
Journal of Neuropathology & Experimental Neurology 78 (8), 709-716, 2019
|A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy|
Z Gharaylou, A Tafakhori, E Agah, V Aghamollaii, A Kebriaeezadeh, ...
CNS drugs 33 (3), 283-291, 2019
|Treatment of Myoclonus–dystonia with carbamazepine|
HS Moghaddam, A Tafakhori, H Darvish, J Mahmoudi-Gharaei, F Jamali, ...
Parkinsonism & Related Disorders 53, 116-117, 2018
|Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo …|
SM Baram, S Karima, S Shateri, A Tafakhori, A Fotouhi, BS Lima, S Rajaei, ...
Inflammopharmacology 27 (6), 1101-1112, 2019
|Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian …|
MH Harirchian, V Aghamollaii, A Tafakhori, S Taslimi, R Shahsiah, ...
IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI) 14 (1), 98-104, 2015